Project Grant R01AI189992
- Federal Project Grant Award Summary The University of South Florida received a $470,953 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2030. This five-year research initiative will produce biomedical research and scientific knowledge concerning the role of SSR42, a regulatory RNA molecule, in virulence factor regulation and pathogenic...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the Regents of the University of Minnesota a $2,999,774 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on maternal microbial exposure and CD8 T cell populations at the maternal-fetal interface (MFI). The award, obligated on July 17, 2025, with a completion date of June 30, 2029, funds fundamental immunological research that...
- Federal Grant Award Summary The University of South Florida received a $375,000 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded June 10, 2025, with performance through May 31, 2030. This award supports biomedical research investigating the functions of membrane-less ribonucleoprotein (mRNP) granules in RNA metabolism within Plasmodium falciparum, the human malaria parasite. The research...
- Federal Project Grant Award Summary The University of South Florida received a Project Grant award of $203,060 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2028. This research initiative focuses on investigating the ecology of Plasmodium malariae transmission in Cameroon, specifically addressing the patchy distribution and seasonal variations of this...
- Federal Grant Award Summary The University of South Florida received a $480,522 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 23, 2025, with completion targeted for June 30, 2030. The award supports fundamental research into the role and regulation of secreted proteases produced by Staphylococcus aureus, a major human pathogen. The research employs protease-null...
- Federal Grant Award Summary Florida State University's Sponsored Research Administration Division received a $372,997 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 10, 2026, through March 31, 2031. The award supports investigator-initiated biomedical research focused on elucidating the regulatory mechanisms of cytosolic DNA sensing pathways through non-canonical...
- Federal Grant Award Summary The University of South Florida received a $412,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 3, 2025 through June 30, 2027. The award supports research focused on evaluating immunodominant fragments of Plasmodium falciparum Glutamic Acid Rich Protein (PfGARP) for malaria vaccine development. The project builds on prior laboratory...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Leland Stanford Junior University a Project Grant totaling $789,442 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 17, 2025, with a completion date of June 30, 2030. This research initiative employs multi-omics approaches—including single-cell proteomic and transcriptomic analyses—to investigate how the immune system adapts to repeated Plasmodium...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Fundacion Instituto De Investigaciones Biotecnologicas a Project Grant of $133,693.00 under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 25, 2025, with a completion date of July 31, 2030. Under this award, the awardee will conduct investigator-initiated biomedical research on the role of an unusual double-variant nucleosome (DVN) composed of H2A.Z and...
- Federal Project Grant Award Summary Mayo Clinic was awarded $689,081 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 1, 2026, with a project completion date of March 31, 2031. The award funds research to establish the etiology and underlying biological mechanisms of villitis of unknown etiology (VUE), an inflammatory placental condition characterized by maternal CD8+ T cell infiltration of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of South Florida a Project Grant of $791,245 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on May 6, 2026, with an anticipated completion date of April 30, 2031. This five-year research initiative, conducted by the Totary-Jain and Coyne laboratories at the Tampa, Florida campus, focuses on elucidating the antiviral defense mechanisms of the placenta through investigation of how human trophoblasts recognize and respond to viral threats at the maternal-fetal interface. The research specifically examines how microRNA (miRNA) clusters derived from short interspersed nuclear elements (SINEs) activate type III interferon signaling to provide protection against intrauterine viral infections. The project delivers scientific research products organized around two specific aims: Aim 1 utilizes advanced organoid models and genetic tools to define the cellular sensors and signaling pathways by which primate-specific C19MC-derived Alu double-stranded RNA (dsRNA) is recognized and drives interferon-lambda release from human trophoblasts; Aim 2 investigates the broader role of C19MC in placental antiviral defense mechanisms. Through this investigator-initiated biomedical research, the award supports basic science investigation into the immunological mechanisms protecting the fetus from pathogens while maintaining immune tolerance, with findings intended to advance understanding of placental immunology and inform future therapeutic interventions for pregnancy-related infectious disease complications.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $791.2k | 5/7/26 |